The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group") and the safety and local tolerability in patients receiving their injection from a healthcare professional (HCP) ("Reference Group").

Inclusion Criteria:

• The patient must give written (personally signed and dated) informed consent for their data to be included in the database for this Post Marketing Surveillance programme and any subsequent analysis.

• The patient must have been receiving treatment with Somatuline Autogel at a stable dose for at least 4 months.

• The patient must have a diagnosis of neuroendocrine tumours

• The patient must be at least 18 years of age

• For patients receiving or intending to receive Somatuline Autogel by home injection:

  • The patient must be able to store Somatuline Autogel safely in a refrigerator in their own home and either collect it from their GP/Pharmacy on a monthly basis, or receive the medication by a home delivery service.

Exclusion Criteria:

• The patient is pregnant or breast-feeding, unless continued treatment with Somatuline Autogel is clearly needed (as determined by the treating clinician).

Patients with neuroendocrine tumours seen in routine clinic